245 related articles for article (PubMed ID: 32526601)
1. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
Moore S; Leung B; Wu J; Ho C
J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
[TBL] [Abstract][Full Text] [Related]
3. Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
Jazieh AR; Sağlam EK; Önal HC; Abdelkader Y; Gaafar R; Dawoud E; Nassar M; Alshorbagy D; El Ashry H; Elsayed M
Clin Lung Cancer; 2022 Jun; 23(4):364-373. PubMed ID: 35277345
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study.
Guan S; Sun J; Wang Y; Han S; Chen C; Yue D; Huang Y; Ren K; Wang J; Wang J; Zhao L
Cancer Immunol Immunother; 2024 May; 73(7):120. PubMed ID: 38713243
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
7. Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
Yusuf D; Walton RN; Hurry M; Farrer C; Bebb DG; Cheung WY
Am J Clin Oncol; 2020 Sep; 43(9):615-620. PubMed ID: 32889830
[TBL] [Abstract][Full Text] [Related]
8. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
10. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
11. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
Guan S; Ren K; Zhang X; Yan M; Li X; Zhao L
Radiat Oncol; 2023 Jul; 18(1):122. PubMed ID: 37491257
[TBL] [Abstract][Full Text] [Related]
14. Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.
Verfaillie S; Lambrecht M; Berkovic P; Dooms C; Nackaerts K; Van de Velde AS; Vansteenkiste J; Wauters E
Cancer Treat Res Commun; 2023; 36():100727. PubMed ID: 37307680
[TBL] [Abstract][Full Text] [Related]
15. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada.
Seung SJ; Hurry M; Walton RN; Evans WK
Curr Oncol; 2020 Aug; 27(4):e354-e360. PubMed ID: 32905267
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
Lim HJ; Lee HY; Lee KS; Han J; Kwon OJ; Park K; Ahn YC; Kim BT; Shim YM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):77-85. PubMed ID: 25374409
[TBL] [Abstract][Full Text] [Related]
18. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience.
Zemanova M; Pirker R; Petruzelka L; Zbozínkova Z; Jovanovic D; Rajer M; Bogos K; Purkalne G; Ceriman V; Chaudhary S; Richter I; Kufa J; Jakubikova L; Zemaitis M; Cernovska M; Koubkova L; Vilasova Z; Dieckmann K; Farkas A; Spasic J; Fröhlich K; Tiefenbacher A; Hollosi V; Kultan J; Kolarová I; Votruba J
Radiol Oncol; 2020 May; 54(2):209-220. PubMed ID: 32463394
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study.
Jazieh AR; Onal HC; Tan DSW; Soo RA; Prabhash K; Kumar A; Huggenberger R; Robb S; Cho BC
J Thorac Oncol; 2021 Oct; 16(10):1733-1744. PubMed ID: 34051381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
